Volume 21, Number 6—June 2015
Research
Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 20131
Table 3
Adverse events reported within 14 days of receipt of oral cholera vaccine, by area, Haiti, 2013*
Adverse event |
Petite Anse, no. (%) |
Cerca Carvajal, no. (%) |
First dose | ||
No. who received dose | 768 | 691 |
Total events reported | 68 (7.9; 95% CI 6.0–10.3) | 56 (8.0; 95% CI 5.4–11.7) |
Common events reported† | ||
Nausea | 20 (2.6) | 17 (2.5) |
Vertigo | 15 (2.0) | 11 (1.6) |
Abdominal pain | 13 (1.7) | 17 (2.5) |
Weakness/fatigue | 11 (1.4) | 4 (0.6) |
Diarrhea | 9 (1.2) | 9 (1.3) |
Vomiting | 5 (0.7) | 5 (0.7) |
Bloating | 3 (0.4) | 7 (1.0) |
Fever | 8 (1.0) | 5 (0.7) |
Headache | 2 (0.3) | 4 (0.6) |
Rash |
4 (0.5) |
Not reported |
Second dose | ||
No. who received dose | 697 | 637 |
Total events reported | 35 (4.7; 95% CI 3.0–7.3) | 29 (4.1; 95% CI 2.4–6.8) |
Common events reported‡ | ||
Vertigo | 6 (0.9) | 7 (1.1) |
Nausea | 7 (1.0) | 5 (0.8) |
Abdominal pain | 6 (0.9) | 9 (1.4) |
Vomiting | 1 (0.1) | 2 (0.3) |
Diarrhea | 2 (0.3) | 4 (0.6) |
Fever | 4 (0.6) | 3 (0.5) |
Weakness/fatigue | 4 (0.6) | 1 (0.2) |
Headache | 3 (0.4) | 3 (0.5) |
Rash | 6 (0.9) | Not reported |
Bloating | 2 (0.3) | Not reported |
*The categories for adverse events are not mutually exclusive as participants had the option to report multiple adverse events.
†Denominator incudes persons who received the first dose. Percentages are unweighted for the purpose of description only.
‡Denominator includes persons who received the second dose. Percentages are unweighted for the purpose of description only.
1Results from this study were partially presented at the 49th US–Japan Conference on Cholera and Other Enteric Bacterial Infections; 2015 Jan 14–16; Gainesville, Florida, USA.